Altimmune, Inc. (ALT) has enrolled the first patient in its multinational Phase 2 clinical trial of HepTcell, a peptide-based immunotherapeutic under development for treatment of chronic hepatitis B. The study is being conducted in the United States, Canada and Europe and is a double-blind, randomized, placebo-controlled study of 80 adult patients. The primary efficacy endpoint is virological response.
"Based on the encouraging preclinical and clinical data we are optimistic that HepTcell may be ideal in combination with novel direct-acting antivirals to achieve a functional cure for this disease," said Scott Harris, Chief Medical Officer of Altimmune.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.